Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A DOSE COMPARISON STUDY OF A NEW TRIAZOLE ANTIFUNGAL (D0870) IN HIV-POSITIVE PATIENTS WITH ORAL CANDIDIASIS
Autore:
DEWIT S; DUPONT B; CARTLEDGE JD; HAWKINS DA; GAZZARD BG; CLUMECK N; DENNING DW;
Indirizzi:
CHU ST PIERRE,DEPT INFECT DIS,322 RUE HAUTE B-1000 BRUSSELS BELGIUM INST PASTEUR PARIS FRANCE ST PIERRE HOSP BRUSSELS BELGIUM CHELSEA & WESTMINSTER HOSP,ST STEPHENS CLIN LONDON ENGLAND UNIV MANCHESTER MANCHESTER LANCS ENGLAND N MANCHESTER GRP HOSP MANCHESTER LANCS ENGLAND
Titolo Testata:
AIDS
fascicolo: 6, volume: 11, anno: 1997,
pagine: 759 - 763
SICI:
0269-9370(1997)11:6<759:ADCSOA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-VITRO ACTIVITY; FLUCONAZOLE; ALBICANS;
Keywords:
OROPHARYNGEAL CANDIDIASIS; HIV PATIENTS; AIDS; TRIAZOLE; D0870;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
S. Dewit et al., "A DOSE COMPARISON STUDY OF A NEW TRIAZOLE ANTIFUNGAL (D0870) IN HIV-POSITIVE PATIENTS WITH ORAL CANDIDIASIS", AIDS, 11(6), 1997, pp. 759-763

Abstract

Objective: This multicentre study evaluated the clinical efficacy andtolerability of D0870 in treating oropharyngeal candidiasis in HIV-positive patients who had no history of clinical resistance to fluconazole. Methods: Three regimens were evaluated in two phases. in phase I a50 mg initial dose was followed by 10 mg for 4 days (Group 1). In phase II a 100 mg initial dose was followed by 25 mg for 4 days (Group 2), or 10 mg for 5 days (Group 3). Results: Clinical cure was obtained in 27 patients of a total of 35 (77%) and six other patients improved (17%). Two patients at the lowest dose failed and both had very low plasma concentration of D0870. No association was found between clinical outcome, minimum inhibitory concentration of D0870 pre-therapy for Candida albicans, maximum recorded plasma D0870 concentration, cfu of culture or CD4 cell count at entry. Overall, 37% of the patients experienced relapse during the 2 weeks post therapy. Tolerance was excellent. Mild adverse events possibly related to the study drug were recorded in five patients. Conclusion: D0870 demonstrates excellent efficacy at low doses in the treatment of HIV-related OPC and exhibits a favourable safety profile.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 11:07:08